Ownership

Beth C. Seidenberg - Insider Trading & Ownership

Entity: Individual
Summary: The estimated net worth of Beth C. Seidenberg is at least $23.8M dollars as of October 30, 2024. Beth C. Seidenberg is the Director of Progyny, Inc. and owns shares of Progyny, Inc. (PGNY) stock worth about $8.67M. Beth C. Seidenberg is the Director of Sagimet Biosciences Inc. and owns shares of Sagimet Biosciences Inc. (SGMT) stock worth about $8.33M. Beth C. Seidenberg is the Director of Vera Therapeutics, Inc. and owns shares of Vera Therapeutics, Inc. (VERA) stock worth about $6.72M. Beth C. Seidenberg is the Director of Atara Biotherapeutics, Inc. and owns shares of Atara Biotherapeutics, Inc. (ATRA) stock worth about $45.1K.
All Insider Reports: All Insider Reports

Ownership of Beth C. Seidenberg

Symbol	Company	Relationship	Holdings Value	Past Year Net Change	Change %	Report Period
PGNY	Progyny, Inc.	Director	$8.67M			May 23, 2024
SGMT	Sagimet Biosciences Inc.	Director	$8.33M			Jun 5, 2024
VERA	Vera Therapeutics, Inc.	Director	$6.72M	-$1.42M	-17.4%	Oct 28, 2024
ATRA	Atara Biotherapeutics, Inc.	Director	$45.1K			May 31, 2023
SLRN	ACELYRIN, Inc.	Director				Jun 7, 2024
KYTX	Kyverna Therapeutics, Inc.	Director, 10%+ Owner				Feb 12, 2024

Showing 1 to 6 of 6 entries

Insider Transactions Reported by Beth C. Seidenberg:

Sym	Company	Class	Transaction	%	Value $	* Price $	Shares	Shares After	Date	Ownership
VERA	Vera Therapeutics, Inc.	Class A Common Stock	Sale	-10.2%	-$720K	48.03	-15K	132K	10/28/2024	Direct
VERA	Vera Therapeutics, Inc.	Class A Common Stock	Sale	-8.62%	-$585K	42.31	-13.8K	147K	9/19/2024	Direct
VERA	Vera Therapeutics, Inc.	Class A Common Stock	Sale	-26.9%	-$62K	42.00	-1.48K	4.01K	9/18/2024	See Footnote
VERA	Vera Therapeutics, Inc.	Class A Common Stock	Sale	-0.73%	-$49.4K	42.01	-1.18K	160K	9/18/2024	Direct
SLRN	ACELYRIN, Inc.	Director Stock Option (right to buy)	Award		$0	0.00	+92.2K	92.2K	6/7/2024	Direct
SGMT	Sagimet Biosciences Inc.	Stock Option (Right to Buy)	Award		$0	0.00	+51.5K	51.5K	6/5/2024	Direct
PGNY	Progyny, Inc.	Common Stock	Award	+19.9%	$0	0.00	+7.21K	43.4K	5/23/2024	Direct
PGNY	Progyny, Inc.	Stock Option (Right to Buy)	Award		$0	0.00	+26.9K	26.9K	5/23/2024	Direct
VERA	Vera Therapeutics, Inc.	Stock Option (right to buy)	Award		$0	0.00	+14K	14K	5/15/2024	Direct
KYTX	Kyverna Therapeutics, Inc.	Common Stock	Conversion of derivative security		$0		+4.52M	3.79M	2/12/2024	See Footnote
KYTX	Kyverna Therapeutics, Inc.	Series B Redeemable Convertible Preferred Stock	Conversion of derivative security	-100%	$0	0.00^*	-7.36M	0	2/12/2024	See Footnote
KYTX	Kyverna Therapeutics, Inc.	Series A-2 Redeemable Convertible Preferred Stock	Conversion of derivative security	-100%	$0	0.00^*	-8.83M	0	2/12/2024	See Footnote
KYTX	Kyverna Therapeutics, Inc.	Series A-1 Redeemable Convertible Preferred Stock	Conversion of derivative security	-100%	$0	0.00^*	-4.4M	0	2/12/2024	See Footnote
SGMT	Sagimet Biosciences Inc.	Series A Common Stock	Conversion of derivative security	+4800.2%	$0		+1.86M	1.9M	7/18/2023	See footnote
SGMT	Sagimet Biosciences Inc.	Series A Common Stock	Award		$0		+38.8K	38.8K	7/18/2023	See footnote
SGMT	Sagimet Biosciences Inc.	Series A Common Stock	Conversion of derivative security		$0		+84.8K	84.8K	7/18/2023	Direct
SGMT	Sagimet Biosciences Inc.	Series A Common Stock	Purchase		$750K	16.00	+46.9K	46.9K	7/18/2023	By trust
SGMT	Sagimet Biosciences Inc.	Common Stock	Disposed to Issuer	-100%	$0		-38.8K	0	7/18/2023	See footnote
SGMT	Sagimet Biosciences Inc.	Series F Preferred Stock	Conversion of derivative security	-100%	$0	0.00^*	-20.4M	0	7/18/2023	See footnote
SGMT	Sagimet Biosciences Inc.	Series E Preferred Stock	Conversion of derivative security	-100%	$0	0.00^*	-103M	0	7/18/2023	See footnote
SGMT	Sagimet Biosciences Inc.	Series D Preferred Stock	Conversion of derivative security	-100%	$0	0.00^*	-6.1M	0	7/18/2023	See footnote
SGMT	Sagimet Biosciences Inc.	Series C Preferred Stock	Conversion of derivative security	-100%	$0	0.00^*	-8.6M	0	7/18/2023	See footnote
SGMT	Sagimet Biosciences Inc.	Series B Preferred Stock	Conversion of derivative security	-100%	$0	0.00^*	-493K	0	7/18/2023	See footnote
SGMT	Sagimet Biosciences Inc.	Series B-1 Preferred Stock	Conversion of derivative security	-100%	$0	0.00^*	-8.6M	0	7/18/2023	See footnote
SGMT	Sagimet Biosciences Inc.	Series A Preferred Stock	Conversion of derivative security	-100%	$0	0.00^*	-539K	0	7/18/2023	See footnote
SGMT	Sagimet Biosciences Inc.	Stock Option (Right to Buy)	Disposed to Issuer	-100%	$0	0.00^*	-23.2K	0	7/18/2023	Direct
SGMT	Sagimet Biosciences Inc.	Stock Option (Right to Buy)	Award		$0	0.00	+23.2K	23.2K	7/18/2023	Direct
SGMT	Sagimet Biosciences Inc.	Series E Preferred Stock	Conversion of derivative security	-100%	$0	0.00^*	-6.74M	0	7/18/2023	Direct
PGNY	Progyny, Inc.	Common Stock	Other	+39.7%	$0	0.00	+10.3K	36.2K	6/23/2023	Direct
PGNY	Progyny, Inc.	Common Stock	Other	-100%	$0	0.00^*	-17.2K	0	6/23/2023	See footnote
PGNY	Progyny, Inc.	Common Stock	Other	+34.5%	$0	0.00	+6.66K	25.9K	6/9/2023	Direct
PGNY	Progyny, Inc.	Common Stock	Other		$0	0.00	+265K	265K	6/9/2023	See footnote
PGNY	Progyny, Inc.	Common Stock	Other	-99%	$0	0.00	-1.65M	17.2K	6/9/2023	See footnote
ATRA	Atara Biotherapeutics, Inc.	Common Stock	Award	+97.1%	$0	0.00	+57K	116K	5/31/2023	Direct
ATRA	Atara Biotherapeutics, Inc.	Non-Qualified Stock Option (Right to Buy)	Award		$0	0.00	+79.5K	79.5K	5/31/2023	Direct
PGNY	Progyny, Inc.	Common Stock	Award	+36.2%	$0	0.00	+5.12K	19.3K	5/24/2023	Direct
PGNY	Progyny, Inc.	Stock Option (Right to Buy)	Award		$0	0.00	+19.7K	19.7K	5/24/2023	Direct
PGNY	Progyny, Inc.	Stock Option (Right to Buy)	Award		$65K	19.93	+3.26K	3.26K	5/24/2023	Direct
VERA	Vera Therapeutics, Inc.	Stock Option (right to buy)	Award		$0	0.00	+20K	20K	5/10/2023	Direct
SLRN	ACELYRIN, Inc.	Common Stock	Purchase		$1.08M	18.00	+60K	60K	5/9/2023	Direct
SLRN	ACELYRIN, Inc.	Common Stock	Purchase	+14.6%	$22.5M	18.00	+1.25M	9.79M	5/9/2023	See footnote
SLRN	ACELYRIN, Inc.	Common Stock	Conversion of derivative security		$0		+8.54M	8.54M	5/9/2023	See footnote
SLRN	ACELYRIN, Inc.	Series C Redeemable Convertible Preferred Stock	Conversion of derivative security	-100%	$0		-2.04M	0	5/9/2023	See footnote
SLRN	ACELYRIN, Inc.	Series B Redeemable Convertible Preferred Stock	Conversion of derivative security	-100%	$0		-2.45M	0	5/9/2023	See footnote
SLRN	ACELYRIN, Inc.	Series A Redeemable Convertible Preferred Stock	Conversion of derivative security	-100%	$0		-4.06M	0	5/9/2023	See footnote
SLRN	ACELYRIN, Inc.	Director Stock Option (right to buy)	Other	-100%	$0	0.00^*	-23.2K	0	5/9/2023	Direct
SLRN	ACELYRIN, Inc.	Director Stock Option (right to buy)	Other		$0	0.00	+23.2K	23.2K	5/9/2023	Direct
SLRN	ACELYRIN, Inc.	Director Stock Option (right to buy)	Award		$0	0.00	+23.2K	23.2K	5/4/2023	Direct
VERA	Vera Therapeutics, Inc.	Class A Common Stock	Purchase	+0.12%	$16.7K	7.24	+2.3K	1.95M	3/30/2023	See Footnote
VERA	Vera Therapeutics, Inc.	Class A Common Stock	Purchase	+1.24%	$173K	7.24	+23.9K	1.95M	3/28/2023	See Footnote

Previous1 2Next

Showing 1 to 50 of 96 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.